Wound infection - postoperative
Methodology & AI Transparency ⓘ
Wound infection - postoperative Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Wound infection - postoperative is an ICD-10-CM indexed diagnosis (T81.40XA) within Bacterial, Viral & Fungal Infections.
- 2 Real-world patient consensus: Federal ICD-10-CM code T81.40XA categorizes Wound infection - postoperative under Bacterial, Viral & Fungal Infections.
- 3 Typical cash cost range: Differential triage of Wound infection - postoperative (T81.40XA) utilizes antimicrobial stewardship (narrow-spectrum in Wound infection - postoperative (T81.40XA: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Objective lab/clinical target for Wound infection - postoperative: Complete Blood Count in Wound infection - postoperative (T81.40XA: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (T81.40XA)) and C-Reactive Protein / in Wound infection - postoperative (T81.40XA: Procalcitonin).
Ask our AI Specialists anything about Wound infection - postoperative
What Is Wound infection - postoperative?
Wound infection - postoperative is an ICD-10-CM indexed diagnosis (T81.40XA) within Bacterial, Viral & Fungal Infections. Clinical evaluation centers on antimicrobial stewardship (narrow-spectrum in Wound infection - postoperative (T81.40XA: pathogen-directed duration) or) alongside serial Complete Blood Count in Wound infection - postoperative (T81.40XA: (WBC & Differential)) tracking (WBC 4.0 – 10.0 x10^3/uL (T81.40XA)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Wound infection - postoperative (ICD-10 T81.40XA) is driven by pathogen-associated molecular pattern in Wound infection - postoperative (T81.40XA: (PAMP) innate immune); specialists in Bacterial, Viral & Fungal Infections monitor C-Reactive Protein / in Wound infection - postoperative (T81.40XA: Procalcitonin) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Wound infection - postoperative (T81.40XA): acute fever, chills, in Wound infection - postoperative (T81.40XA: malaise, and myalgias)
- • Secondary Wound infection - postoperative clinical sign: sore throat, productive in Wound infection - postoperative (T81.40XA: cough, sinus/ear pain,)
- • Symptom flares in Wound infection - postoperative correlating with Complete Blood Count in Wound infection - postoperative (T81.40XA: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (T81.40XA)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Wound infection - postoperative (T81.40XA: pathogen-directed duration) or) evaluation (T81.40XA)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Wound infection - postoperative Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | T81.40XA | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Wound infection - postoperative (T81.40XA: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (T81.40XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Wound infection - postoperative (T81.40XA: Procalcitonin) | Resolution to baseline (T81.40XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Wound infection - postoperative (T81.40XA: Culture & Sensitivity) | Pathogen clearance / negative test (T81.40XA) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Wound infection - postoperative
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Cefadroxil Duricef • RxCUI 309049 | Cephalosporin Antibacterial | 83% | $0.1964 | $ 10.51 /mo |
| Lopinavir and Ritonavir Kaletra • RxCUI 311369 | Protease Inhibitor | 92% | $5.2003 | $ 185.00 /mo |
| Tenofovir Disoproxil Fumarate Viread • RxCUI 349251 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 84% | $0.2938 | $ 10.80 /mo |
| Emtricitabine and Tenofovir Disoproxil Fumarate Truvada • RxCUI 476556 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 93% | $59.5926 | $ 185.00 /mo |
| Bethanechol Chloride Urecholine • RxCUI 857321 | Cholinergic Muscarinic Agonist | 78% | $0.0987 | $ 7.26 /mo |
| Atazanavir Reyataz • RxCUI 402245 | Protease Inhibitor | 92% | $1.0536 | $ 26.11 /mo |
| Ansuvimab Ebanga • RxCUI 2472156 | Zaire Ebolavirus Glycoprotein-directed Antibody | 76% | $1.6700 | $ 76.13 /mo |
| Cabotegravir and Rilpivirine Cabenuva • RxCUI 2475415 | FDA Prescription Therapeutic Agent | 79% | $1.3100 | $ 61.56 /mo |
| Doravirine Pifeltro • RxCUI 2055760 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 83% | $59.5992 | $ 185.00 /mo |
| Amisulpride Barhemsys • RxCUI 2284232 | Dopamine-2 Receptor Antagonist | 93% | $1.0900 | $ 52.65 /mo |
| Metronidazole Noritate, Vagizole • RxCUI 311681 | Nitroimidazole Antimicrobial | 88% | $0.0999 | $ 6.08 /mo |
| Trimethobenzamide Hydrochloride Tigan • RxCUI 860771 | Antiemetic | 83% | $17.9997 | $ 185.00 /mo |
| Nevirapine Viramune • RxCUI 199422 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 82% | $0.1383 | $ 8.73 /mo |
| Bromfenac Sodium Bromfenac Ophthalmic Solution, Prolensa • RxCUI 1375917 | Nonsteroidal Anti-inflammatory Drug | 89% | $11.7673 | $ 23.25 /mo |
| Ritonavir Norvir • RxCUI 152971 | Cytochrome P450 3A Inhibitor | 86% | $8.3281 | $ 19.77 /mo |
| Urea Milkbodylotion, Urevex • RxCUI 198342 | FDA Prescription Therapeutic Agent | 74% | $0.1462 | $ 14.42 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Wound infection - postoperative)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on How the body absorbs the medicine and safety comparison of Zamerovimab and: What a 735-Participant Study Found Zamerovimab and Mazorelvimab achieves earlier and higher RVNA titers than HRIG across diverse wound types, with comparable safety. Biologicals : journal of the International Association of Biological Standardization • 2025-11-15 • Phase III Randomized Trial | N = 735 | 93/100 | PMID 40812204 ↗ |
| New Insights on Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized: What a 302-Participant Study Found CONCLUSIONS: These interim study results support further evaluation of molnupiravir as a potential treatment to reduce hospitalizations and/or death in nonhospitalized patients with Covid-19. NEJM evidence • 2022-02-15 • Phase III Randomized Trial | N = 302 | 93/100 | PMID 38319179 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of a China-developed live attenuated herpes zoster vaccine in The trial included 25 000 participants. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2026-01-15 • Phase III Randomized Trial | N = 13 | 88/100 | PMID 40962113 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical effectiveness of transversus abdominis plane block versus local TAP block does not appear to provide a greater opioid-sparing effect than LAWI of trocar insertion sites after laparoscopic appendicectomy in children, when combined with systemic multimodal pain-relieving including... European journal of anaesthesiology • 2026-10-01 • Phase III Randomized Trial | N = 50 | 88/100 | PMID 41777031 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of skin-applied moxifloxacin on therapeutic laparoscopy-induced wound The results of the current clinical trial demonstrated that the use of applied to the skin MXF could be a potential option to expedite therapeutic laparoscopy-induced wound healing by reducing redness, oedema, ecchymosis, and... BMC surgery • 2025-05-06 • Phase III Randomized Trial | N = 80 | 88/100 | PMID 40329263 ↗ |
Wound infection - postoperative Patient Community & “People Like Me” Threads
Filter Wound infection - postoperative community threads and patient logs by age, biological sex, dosage, and treatment duration.